Live Quote · NASDAQPTNHealthcare · Biotechnology

Palatin Technologies, Inc.

$11.59▲ 12.20%(+$1.26)

TickerSpark Score

44/100

▌ Weak

70

Valuation

40

Profitability

10

Growth

68

Health

30

Momentum

Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PTN research report →

52-Week Range25% of range

Low

$5.00

Current

$11.59

High

$31.00

Company Overviewpalatin.com

About the company

Palatin Technologies, Inc. , a biopharmaceutical company, develops first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system in the United States. It is developing oral small molecule PL7737 MC4R agonist in preclinical studies; long-acting peptide MC4R agonists; and Bremelanotide co-administration with Tirzepatide to treat obesity in Phase 2 trial, as well as Bremelanotide co-formulated with a PDE5i for the treatment of ED in patients not adequately responsive to PDE5i monotherapy.

CEO: Carl Spana
IPO: 1997
Employees: 29
HQ: Monmouth Junction, NJ, US

Price Chart

+54.53% · this period

Valuation

Market Cap: $301.41M
P/E: -2.49
P/S: 23.39
P/B: 1.06
EV/EBITDA: -47.46
Div Yield: 0.00%

Profitability

Gross Margin: 99.76%
Op Margin: -50.60%
Net Margin: -48.50%
ROE: -141.40%
ROIC: -59.93%

Growth & Income

Revenue: $0 · -100.00%
Net Income: $-17,307,349 · 41.80%
EPS: $-32.15 · -1491.58%
Op Income: $-17,459,939
FCF YoY: 32.37%

Performance & Tape

52W High: $31.00
52W Low: $5.00
50D MA: $15.35
200D MA: $15.70
Beta: -0.11
Avg Volume: 17.40K

Get TickerSpark's AI analysis on PTN

Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.

Get Pro Access →

Already have an account? Log in

Form 4 · Filings

Recent insider transactions

Who's buying, who's selling, and how much.

Date	Insider	Role	Type	Shares	Value
Dec 30, 25	WILLS STEPHEN T	officer: Executive VP and CFO/COO	other	26	$555.88
Dec 30, 25	WILLS STEPHEN T	officer: Executive VP and CFO/COO	other	91	$1.95K
Dec 30, 25	WILLS STEPHEN T	officer: Executive VP and CFO/COO	other	95	$2.03K
Dec 30, 25	SPANA CARL	director, officer: President and CEO	other	40	$855.2
Dec 30, 25	SPANA CARL	director, officer: President and CEO	other	138	$2.95K
Dec 30, 25	SPANA CARL	director, officer: President and CEO	other	143	$3.06K
Dec 24, 25	WILLS STEPHEN T	officer: Executive VP and CFO/COO	sell	565	$9.46K
Dec 9, 25	WILLS STEPHEN T	officer: Executive VP and CFO/COO	other	495	$45.29K
Dec 9, 25	WILLS STEPHEN T	officer: Executive VP and CFO/COO	other	518	$56.72K
Dec 9, 25	WILLS STEPHEN T	officer: Executive VP and CFO/COO	other	142	$51.48K

Coverage · PTN

Our PTN coverage

Recent articles, reports, and earnings notes.

View all →

IPO

Should You Buy the Palatin Technologies IPO? Here's the Setup

Palatin Technologies, Inc. (NASDAQ: PTN) is expected to list on May 29, 2026, but the price range has not been disclosed. The company is not a traditional IPO: it is a long-public biotech moving to Nasdaq via a resale registration tied to warrant exercises. The bull case is pipeline leverage in obesity and rare disease; the bear case is dilution, losses, and a very tight cash position.